Art

J-GLOBAL ID：200902177308833088   Reference number：02A0058907

Evaluation of HER2 Status: For the Treatment of Metastatic Breast Cancer by Humanized Anti-HER2 Monoclonal Antibody(Trastuzumab)(Pathological Committee for Optimal Use of Trastuzumab).

HER2状態の評価:ヒト化抗-HER2単クローン抗体(トラスツズマブ)(トラスツズマブの最適利用のための病理学委員会)による転移性乳癌の治療に向けて

Author (9)： Uemura S (Tokai Univ. School of Medicine, JPN) ,  Sakamoto G (Tohoku Univ. Scool of Medicine, JPN) ,  Tsuda H (National Defense Medical Coll., JPN) ,  Kurosumi M (Saitama Cancer Center Hospital, JPN) ,  Watanabe T (National Cancer Center Hospital, JPN) ,  Toi M (Tokyo Metropolitan Komagome Hospital, JPN) ,  Hasegawa T (National Cancer Center Res. Inst., JPN) ,  Osamura R Y (Tokai Univ. School of Medicine, JPN) ,  Sasano H (Tohoku Univ. Scool of Medicine, JPN)
Material： Breast Cancer  (Journal of the Japanese Breast Cancer Society)
Volume： 8  Issue： 4  Page： 316-320  Publication year： Oct. 31, 2001 
JST Material Number： L3971A  ISSN： 1340-6868  Document type： Article
Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Reference (38)：

• SLAMON, D. J. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235, 177-182
• SESHADRI, R. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer.The South Australian Breast Cancer Study Group. J Clin Oncol. 1993, 11, 1936-1942
• PAIK, S. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998, 90, 1361-1370
• THOR, A. D. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998, 90, 1346-1360
• LEITZEL, K. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol. 1995, 13, 1129-1135

Terms in the title (9)： HER2 ,  評価 ,  単クローン抗体 ,  トラスツズマブ ,  最適利用 ,  病理学 ,  委員会 ,  転移性乳癌 ,  治療